Cytokinetics Investor Sues Over Heart Drug Approval Claims

By Katryna Perera · September 18, 2025, 8:50 PM EDT

Biopharmaceutical company Cytokinetics and its CEO have been hit with a proposed investor class action in California federal court alleging they made false and misleading statements about the regulatory timeline for...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Seidman v. Cytokinetics, Incorporated et al

Case Number

3:25-cv-07923

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

September 17, 2025